Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase II Psoriasis Trial

Evelo Biosciences, Inc. announced that its first extracellular vesicle product candidate, EDP2939, has progressed to dosing in a Phase II psoriasis clinical trial after completing a safety and tolerability review from a first cohort of human volunteers.